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My patient can’t breathe. From across the busy, open ward, you can see the plaques of Kaposi’s sarcoma riddling 
her skin. The impressive woody edema has 
enlarged her legs to the size of small tree trunks. 
We don’t have access to confirmatory pulmo-
nary testing in Kenya, but she probably wouldn’t 
survive a bronchoscopy anyway.
When she dies six hours later, we can be pret-
ty sure that it is her pulmonary Kaposi’s sarcoma, 
along with her underlying HIV, that killed her. 
Her family tells us that she had dark spots on 
her skin and swelling in her legs for more than 
a year before she presented to the hospital. Like 
many of our patients in East Africa, she sought 
help from a traditional healer for many months 
before turning to the biomedical health system, 
only hours before her death.
Lack of access to diagnostic tools, limited 
early intervention, and inadequate treatment are 
common barriers to improving global health. 
However, increasing awareness, interest, and 
funding in the area of global health means that 
dermatologists and investigators like ourselves 
now have growing opportunities to make a real 
difference. In resource-poor settings, skin dis-
ease is often the presenting complaint that brings 
patients into the health-care system. At one end 
of the spectrum are diseases with fatal conse-
quences, such as Kaposi’s sarcoma. On the other 
end are more quotidian but often stigmatizing 
conditions such as scabies, tinea, or zoster.
This year, the World Health Organization 
(WHO) will publish, for the first time, a com-
prehensive treatment guideline and diagnostic 
algorithm for the most common HIV-related 
skin conditions. The Guidelines on Skin and 
Oral HIV-Associated Conditions in Children 
and Adults will help health professionals and 
policy makers provide appropriate therapy for 
Kaposi’s sarcoma, seborrheic dermatitis, her-
pes zoster, scabies, papular pruritic eruption, 
eosinophilic folliculitis, tinea, molluscum, drug 
reactions, and oral candidiasis (World Health 
Organization, in press). These conditions have 
a high prevalence in developing countries, but 
many lack internationally agreed-on standards 
of care. This deficit led to inconsistent and some-
times dangerous treatment approaches or lack of 
essential drugs. Critically, dermatologists were 
involved at all levels of the guideline-develop-
ment process, including Cochrane reviews of the 
literature, guideline development and review, 
and additional funding for the project from 
the International Foundation for Dermatology 
(http://www.ifd.org).
Although diseases such as Kaposi’s sarcoma 
and scabies are not necessarily major issues in 
the US health-care system, many skin condi-
tions pose critical mortality and quality-of-life 
issues at the global level. Dermatologists based 
in resource-rich settings such as North America 
and Europe now have a launchpad from which 
to make significant contributions to contribute 
to global health. And, in turn, global health can 
serve as an entry point for the field of dermatol-
ogy on the world stage. 
There are three key ways in which dermatolo-
gists can assist in this growing effort: become 
champions in health-policy organizations 
on national and international levels, perform 
research with an eye to diseases that affect the 
poorest populations in the world, and participate 
in global health education for trainees locally 
and abroad. After presenting a brief background, 
we explore these three avenues in more detail 
below.
A background on skin and the WHO
The Guidelines for HIV-Associated Skin and 
Oral Conditions emerged in response to pro-
viders in need. Practitioners and managers in 
low-resource settings specifically asked the US 
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Centers for Disease Control and Prevention (CDC) for guid-
ance in the area of skin disease as a priority. This request sur-
prised at least one CDC official with whom I spoke. Although 
skin diseases are one of the most common reasons for pre-
sentation to primary-care settings in tropical countries and 
disproportionately affect vulnerable groups such as children, 
they are often considered “small-time players” (Hay et al., 
2006). It was because of this request—from the level of those 
practicing in the field—that the CDC provided funding to the 
WHO for research and guideline development in the area of 
HIV-associated skin disease.
Expanding the role of dermatology within large organi-
zations that affect global policy, such as the WHO, is highly 
relevant to our specialty. Establishing partnerships to ensure 
that high-quality dermatologic research informs international 
health policy is critical to developing quality policies, spread-
ing knowledge about skin disease more widely, and improving 
prevention and treatment globally. Barbara Gilchrest’s desig-
nation of unity in action as this year’s theme for the JID signi-
fies unity not only across the dermatologic community but also 
with the larger medical community beyond our specialty, both 
nationally and internationally (Gilchrest, 2014). For example, 
dermatology has been conspicuously absent from the agenda 
of HIV/AIDS policy makers; there have been few abstracts 
in the area of dermatology at the largest HIV/AIDS meeting 
such as the International AIDS Conference. With efforts such 
as the WHO Guidelines for HIV-Associated Skin and Oral 
Conditions, our HIV patients suffering from skin disease have 
become relevant to the overall fight against HIV.
Prior WHO guidance in the field of dermatology is 
extremely limited. Disease-specific treatment recommen-
dations include those issued for leprosy, Buruli ulcer, and 
leishmaniasis. INTERSUN, a global UV-light program that 
addresses UV’s health effects and sun protection, authored 
two of the relatively few WHO publications in the field of 
dermatology, Artificial Tanning Sunbeds: Risks and Guidance 
and Sun Protection and Schools in 2003 (World Health 
Organization, 2003a, 2003b).
Therefore, this year’s WHO guidelines represent a new 
chapter in the collaborative effort in international health pol-
icy in the field of dermatology. But the guidelines represent 
only a whisper of the future role that dermatology could play 
in the field of global health and international health policy.
Global health champions
To expand dermatology’s role, dermatology champions are 
needed to participate in committees and work groups within 
health policy organizations. Although few in number, der-
matologists have played key roles at the WHO. For exam-
ple, Robert Chalmers co-leads the Topic Advisory Group for 
Dermatology, tasked with reviewing upcoming International 
Classification of Diseases–11th Revision coding. This impor-
tant effort will ultimately affect all who care for patients 
and bill for diagnoses and services rendered. Roderick Hay 
(chair of the International Foundation for Dermatology) 
has served on the Committee on the Selection and Use of 
Essential Medicines for many years. This committee chooses 
the limited range of medicines considered essential across 
the globe, which ultimately dictates formulary choices at the 
country level and determines which treatments patients in 
rural Africa are likely to have access to.
Finally, two recent victories for the field of dermatology at 
the level of the WHO are (i) the addition of scabies to the 
list of neglected tropical diseases and (ii) the endorsement by 
the 67th World Health Assembly of psoriasis as a research 
and health-care quality-improvement priority. These con-
tributions to our field serve as examples of dermatologists 
identifying structures, such as committees, work groups, 
or advisory panels, on which they may serve and making 
an impact on policy at the international level, which will 
ultimately affect the lives of our patients suffering from skin 
disease. We need more such champions in our midst.
Global health research
Developing research projects to describe the multinational 
burden of skin conditions is also critical. There are several 
current international efforts to highlight the burden of skin 
disease worldwide, which will help raise the profile of skin 
conditions affecting our patients and ultimately translate into 
allocation of health resources. Most notable is the Disease 
Control Priorities Project, which includes the global burden 
of disease. As published in the JID, skin disease worldwide is 
the fourth leading nonfatal cause of years lost due to disabil-
ity, ahead of diabetes, asthma, and chronic obstructive pul-
monary disease (Hay et al., 2014). This ranking may actually 
underestimate the true impact of skin disease, as conditions 
such as melanoma are counted separately under cancer, 
leishmaniasis under infectious disease, and the effects of sys-
temic lupus erythematosus under musculoskeletal disease.
Research in the area of dermatologic health-care delivery 
in resource-poor settings is also key. When there are only a 
handful of dermatologists for an entire country, delivery of 
care must follow a different model. For example, a recent 
study by our collaborators in Uganda shows that in rural 
Africa, where diagnosis of Kaposi’s sarcoma is often made on 
clinical impression alone or delayed until excision by a sur-
geon can be scheduled, training nurses and low-level clinic 
staff in skin biopsy techniques allows for safe, correct, and 
more rapid diagnosis (Laker-Oketta et al., 2013). My Kenyan 
patient might have been diagnosed with Kaposi’s sarcoma 
much earlier if such a service existed in her area.
Finally, high-quality disease-specific research on skin con-
ditions affecting large numbers of people globally, not just in 
the United States, must be expanded. For the Guidelines on 
HIV-Associated Skin and Oral Conditions, Cochrane reviews 
of the literature were performed or updated on all 11 of the 
HIV-associated conditions mentioned previously. All the 
recommendations were based on evidence quality that was 
considered “low” or “very low” (Guyatt et al., 2008), with 
the single exception of the evidence on the treatment for oral 
candidiasis. Clearly, we still have much to improve on in 
terms of the breadth and quality of our evidence base.
Global health education
Education in global health consists of two parts: educat-
ing domestic trainees in global health issues, including skin 
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diseases that are prevalent in other parts of the world, and 
training providers in skin health in the developing world. 
Domestically, there are centers of expertise in global health 
dermatology at the University of California at San Francisco, 
the University of Pennsylvania, Boston University, and 
my home institution of Harvard University/Massachusetts 
General Hospital, among others. Interest in global health is 
growing in general: trainees enrolling in global health pro-
grams doubled over a period of just three years, according 
to the Consortium of Universities for Global Health (Emory 
University, 2014). The American Academy of Dermatology’s 
resident international grant to Botswana, organized by 
Carrie Kovarik, is consistently oversubscribed (http://www.
aad.org/education/awards-grants-and-scholarships/resident-
international-grant).
Internationally, the Regional Dermatology Training Centre 
in Tanzania trains clinical officers and nurses in dermatology 
(http://www.ifd.org/the-regional-dermatology-training-
centre,-tanzania). Toby Maurer (University of California at 
San Francisco) is working to establish a dermatology resi-
dency in Kenya and Uganda with the aim of offering high-
quality training to providers in some of the neediest settings. 
The International Society of Dermatology’s task force “Skin 
Care for All: Community Dermatology,” led by Terence Ryan, 
has produced a freely available dermatologic public health 
syllabus (http://www.skincareforall.org/capacity-to-benefit). 
In addition to these formalized programs, education can take 
the form of handbooks, reference manuals, and even inter-
national guidelines such as the one on HIV-associated skin 
conditions discussed here. These efforts make a substantial 
contribution, but we need more. More does not mean just 
new programs; it can also be the dissemination of existing 
knowledge or guidelines to a wider global audience.
A call we cannot ignore
Dermatologists have a lot to offer to the field of global health, 
and global health can help the dermatologic community 
gain traction in international health policy, ultimately secur-
ing better care for millions of patients suffering from skin dis-
ease. We must not relax our efforts to remind the world that 
skin health matters. The three mechanisms proposed here are 
(i) developing champions to serve on committees in health 
policy organizations, both national and international, such 
as the WHO; (ii) pursuing quality research with an interna-
tional and epidemiologic focus; and (iii) expanding the role 
of global health in the education of our trainees at home and 
our role in dermatologic education abroad. The pace will 
be slow, but the result will be that no patient anywhere in 
the world will slowly suffocate from Kaposi’s sarcoma sim-
ply because the care needed wasn’t part of the community’s 
training.
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